Tongce Medical's acquisition of 29% of Heren Technology will become the largest shareholder; Zhongsheng Pharmaceutical's oral anti-new coronavirus innovative drug RAY1216 clinical trial is approved

Key Data Concepts:   

? These are the company names, stock quotes, topics, and entities related to this data.

000155 002317 300376 300550 300713 China Shipbuilding Industry Group Power Citic Securities East Group Co Fujian Funeng Guangdong Zhongsheng Pharmaceutical Heren Health Shenzhenrease Technology Sichuan New Energy Power Company Limited Topchoice Medical Inc Xinjiang Sayram Modern Agriculture Science, Technology Restructuring, Recapitalisation Shareholder Management Strategy, Marketing Patent, Copyright, Trademark Research, Development Pharmaceutical Energy, Resource Financial, Business Service Banking Bonds Investments Market, Exchange Biotechnology Technology, Engineering Pool Transfer Asset Management Pet Product, Service Wind Power Economy, Business, Finance Environment

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Home » News » Tongce Medical's acquisition of 29% of Heren Technology will become the largest shareholder; Zhongsheng Pharmaceutical's oral anti-new coronavirus innovative drug RAY1216 clinical trial is approved